þÿ
...Similarly, trials can use several doses of test drug and several doses of an active control.....cannot be explained by some characteristic of the study, only superiority of the test drug.....means of a trial showing non-inferiority of the test drug to a standard agent needs to address..
http://www.fda.gov/cder/guidance/4155fnl.pdf (score=100)

X:\TRANSFER\GUIDANCE\CLIN3.WPD
...effects of the test drug on the metabolism of other drugs and the effects of other drugs on its.....metabolic differences between and within individuals and the importance of certain drug.....measurement of blood levels before and after treatment with a test drug (interaction..
http://www.fda.gov/cder/guidance/clin3.pdf (score=67)

þÿ
...The nature of the patient population and the extent of exposure, both for test drug and control.....understand the exposure of study subjects to the test drug or control agent and how safety data.....Studies on potential drug-drug or drug-food interactions should be summarized in the Summary of..
http://www.fda.gov/cder/guidance/4539E.pdf (score=67)

International Conference on Harmonisation of Technical Requirements for...
...This design reveals D/R relationships for the test drug and other drug alone and in combination.....In a factorial study, placebo, and one or more doses of the test drug T and another drug D are.....Studies in which additional drugs are added to the test drug to achieve an adequate response..
http://www.fda.gov/cder/guidance/3774dft.htm (score=51)

þÿ
...blood pressure that could have pharmacologic actions similar to the study drug.In general.....This design reveals D/R relationships for the test drug and other drug alone and in.....In a factorial study, placebo, and one or more doses of the test drug T and another..drug D are..
http://www.fda.gov/cder/guidance/3774dft.pdf (score=51)

Inside Clinical Trials: Testing Medical Products in People
...Randomization increases the likelihood that the groups of people receiving the test drug or.....A treatment could be a drug, medical device, or biologic, such as a vaccine, blood product.....Clinical trials, also known as clinical studies, test potential treatments in human..
http://www.fda.gov/fdac/features/2003/503_trial.html (score=27)

Letter to Rick Potter, New Hampshire Pharmacists Association: April 20, 2004
...To demonstrate bioequivalence, scientists must measure the time it takes for the test drug to.....Indeed, it is often assumed that a drug sold in Canada is the same or very similar to.....drug. The test drug must deliver the same amount of active ingredients into the bloodstream in the..
http://www.fda.gov/oc/opacom/hottopics/importdrugs/potter042004.html (score=27)

ICH E1A
...during clinical drug development is not expected to characterize rare adverse events, for.....causality relationship between adverse events observed and the test drug. There was general.....adverse event rates to be made between the test drug and the control drug, no direct..
http://www.fda.gov/cder/guidance/iche1a.pdf (score=27)

Guidance for Industry
...16 Also, combined images may refer to results from the test drug and modality plus images from.....In studies that compare the effects of a test agent with another drug, biological product.....safety and effectiveness of the drug in humans, or if the radioactive drug has a pharmacological effect in the body,an IND is..
http://www.fda.gov/cder/guidance/5742prt3.pdf (score=27)

/a//content.20090
...Pharmacokinetic studies of absorption, distribution, metabolism, and excretion of the drug.....For studies designed to test drug efficacy in triglyceride..reduction, enrollment in most.....The test drug should also be..compared to a reference drug of the same chemical class, if..
http://www.fda.gov/cder/guidance/lipid.pdf (score=27)

Alpha1-Proteinase Inhibitor (Human), Aralast - Package Insert
...Twenty-eight subjects were randomized to receive either test drug or control drug, 60 mg/kg.....Following their first 10 weekly infusions, the subjects who were receiving control drug.....A clinical study was conducted to compare Aralast (test drug) to a commercially available..
http://www.fda.gov/cber/label/alphalp122302lb.htm (score=27)

C:\Data\My Documents\50785.ap.92502.doc
...Serious adverse events considered suspected or probably related to test drug were reported in 0.....in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse.....possible clinical applicability in body sites where the drug is physiologically..
http://www.fda.gov/cder/foi/label/2002/50785lbl.pdf (score=19)

A Drug Review Glossary
...An application that a drug sponsor must submit to FDA before beginning tests of a new drug.....Studies that test a drug on animals and other nonhuman test systems. They must comply with.....drug, including its structural formula, animal test results, and manufacturing information..
http://www.fda.gov/fdac/special/newdrug/bengloss.html (score=19)

...In BE studies, an applicant compares the systemic exposure profile of a test drug product to.....The drug content of the test product cannot differ from that of the reference listed product by more than 5.....For ANDAs, we also recommend that the BE study be conducted between the test product and reference listed drug using the..
http://www.fda.gov/cder/guidance/5356fnl.doc (score=19)

Guidance for Industry: Developing Medical Imaging Drug and Biological...
...not be sufficient simply to demonstrate that the results of the test drug were used to direct a.....whether use of the test drug results in fewer or greater numbers of unnecessary biopsies.....implementing regulations, FDA cannot approve a drug without evidence that the drug's..
http://www.fda.gov/cber/gdlns/medimageind.pdf (score=19)

Orange Book Preface
...the rate and extent of absorption of the test drug do not show a significant difference from.....the extent of absorption of the test drug does not show a significant difference from the.....Single doses of the test and reference drug products are administered and blood or plasma levels of the drug..
http://www.fda.gov/cder/ob/docs/preface/ecpreface.htm (score=19)

Guidance for Industry: Catheter-Related Bloodstream Infections - Developing...
...A single superiority trial of the test drug may be sufficient under the circumstances outlined.....The sponsor should make sure that the same standard of care is used in both the study drug and comparator drug.....clinical and microbiologic response) at the test-of-cure visit will be the primary..
http://www.fda.gov/cder/guidance/3385dft.htm (score=19)

E 10 Choice of Control Group and Related Issues in Clinical Trials
...Similarly, trials can use several doses of test drug and several doses of an active control.....Use of concomitant non-protocol medication or other treatment that interferes with the test.....A superiority study favoring the test drug, on the other hand, is readily interpretable as..
http://www.fda.gov/cder/guidance/4155fnl.htm (score=19)

Guidance for Industry E 10 Choice of Control Group and Related Issues in...
...Similarly, trials can use several doses of test drug and several doses of an active control.....cannot be explained by some characteristic of the study, only superiority of the test drug.....means of a trial showing non-inferiority of the test drug to a standard agent needs to address..
http://www.fda.gov/cber/gdlns/clincontr0501.pdf (score=19)

In Vivo Drug Metabolism/Drug Interaction Studies -  Study Design, Data...
...Specific enzymes have been identified as metabolizing the test drug, but no in vivo or in vitro.....Previous guidance from FDA on the use of in vitro approaches to study drug metabolism and metabolic drug-drug interactions is.....test drug and other less potent specific inhibitors, or give advice on dosage adjustment..
http://www.fda.gov/cder/guidance/2635fnl.htm (score=19)

Las Vegas Injury Lawyer